At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,236 enrolled
Drug / intervention
Varilrix HSA-free +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.
In Brief
A Phase 3 clinical trial evaluating Varilrix HSA-free and Varilrix™ for Chicken-pox Illness (Varicella Virus Disease) and Chickenpox. Completed, enrolled 1,236 participants across 23 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEstonia, Germany, Mexico, Thailand, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionOct 2016
TodayJul 2026
First PostedOct 7, 2015
Enrollment StartNov 13, 2015
Primary CompletionOct 25, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.7 years ago
Interventions
Varilrix HSA-freebiological
2 doses will be administered, one at Day 0 and the other at Day 42
Varilrix™biological
2 doses will be administered, one at Day 0 and the other at Day 42